Detalhe da pesquisa
1.
Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS).
J Am Acad Dermatol
; 90(3): 494-503, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-37951245
2.
Implementing well-being in the management of psoriasis: An expert recommendation.
J Eur Acad Dermatol Venereol
; 38(2): 302-310, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-37822008
3.
SARS-CoV-2 infection among psoriasis patients in Germany: Data from the German registries PsoBest and CoronaBest.
J Dtsch Dermatol Ges
; 2024 May 22.
Artigo
Inglês
| MEDLINE | ID: mdl-38778439
4.
Bimekizumab maintenance of response through 3â years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial.
Br J Dermatol
; 188(6): 749-759, 2023 05 24.
Artigo
Inglês
| MEDLINE | ID: mdl-36967713
5.
Activation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditions.
Immunity
; 40(6): 989-1001, 2014 Jun 19.
Artigo
Inglês
| MEDLINE | ID: mdl-24909886
6.
Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study.
J Am Acad Dermatol
; 89(1): 36-44, 2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-36870370
7.
Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: Results from the EMBRACE randomized trial.
J Eur Acad Dermatol Venereol
; 37(2): 348-355, 2023 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-36300769
8.
Characterization of patients with psoriatic arthritis in dermatologic and rheumatologic care: analysis of two registries.
J Dtsch Dermatol Ges
; 21(10): 1170-1176, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-37653583
9.
Absolute Psoriasis Area and Severity Index as a valuable marker to determine initial treatment response in psoriasis patients treated with guselkumab in routine clinical care.
Dermatol Ther
; 35(1): e15193, 2022 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34741783
10.
Reaching Treatment Goals in Psoriasis with Conventional Systemic Drugs: How Long Are We Willing to Wait?
Dermatology
; 238(2): 292-300, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-34107489
11.
Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients.
Dermatology
; 238(4): 615-619, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-34775387
12.
Application of the Statistical Method to Convert Published PASI 50/75/90/100 into Absolute PASI Response Rate in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Tildrakizumab Based on Data from the Two Pivotal Phase 3 Studies reSURFACE 1 and reSURFACE 2.
Dermatology
; 238(5): 910-918, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-35168231
13.
A Structured Intervention for Medical Students Significantly Improves Awareness of Stigmatisation in Visible Chronic Skin Diseases: A Randomised Controlled Trial.
Acta Derm Venereol
; 102: adv00641, 2022 Jan 31.
Artigo
Inglês
| MEDLINE | ID: mdl-34904689
14.
Time to Loss of Response following Withdrawal of Ixekizumab in Patients with Moderate-to-Severe Psoriasis.
Acta Derm Venereol
; 102: adv00672, 2022 Mar 15.
Artigo
Inglês
| MEDLINE | ID: mdl-35170742
15.
Subgroup Analyses by European Country-Specific Reimbursement Requirements Confirm Efficacy for Ixekizumab in Psoriasis.
J Drugs Dermatol
; 21(6): 659-667, 2022 Jun 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35674763
16.
Generalized pustular psoriasis: overview of the status quo and results of a panel discussion.
J Dtsch Dermatol Ges
; 20(6): 753-771, 2022 06.
Artigo
Inglês
| MEDLINE | ID: mdl-35674482
17.
Sex and Age Influence the Associated Risk of Depression in Patients with Psoriasis: A Retrospective Population Study Based on Diagnosis and Drug-Use.
Dermatology
; 237(4): 595-602, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-32927456
18.
Effectiveness of a structured short intervention against stigmatisation in chronic visible skin diseases: Results of a controlled trial in future educators.
Health Expect
; 24(5): 1790-1800, 2021 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34318568
19.
[Recommendations when switching therapy from immunosuppressive drugs to dupilumab in patients with atopic dermatitis]. / Handlungsempfehlung zur Therapieumstellung von Immunsuppressiva auf Dupilumab bei Patienten mit atopischer Dermatitis.
Hautarzt
; 72(4): 321-327, 2021 Apr.
Artigo
Alemão
| MEDLINE | ID: mdl-33175219
20.
Documentation of psoriasis in routine care - expert consensus on a German data set.
J Dtsch Dermatol Ges
; 19(10): 1463-1475, 2021 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34622544